These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity. Gu M; Zhou X; Sohn JH; Zhu L; Jie Z; Yang JY; Zheng X; Xie X; Yang J; Shi Y; Brightbill HD; Kim JB; Wang J; Cheng X; Sun SC Nat Immunol; 2021 Feb; 22(2):193-204. PubMed ID: 33398181 [TBL] [Abstract][Full Text] [Related]
4. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice. Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014 [TBL] [Abstract][Full Text] [Related]
5. Cutting Edge: Elevated Glycolytic Metabolism Limits the Formation of Memory CD8 Tabilas C; Wang J; Liu X; Locasale JW; Smith NL; Rudd BD J Immunol; 2019 Nov; 203(10):2571-2576. PubMed ID: 31597706 [TBL] [Abstract][Full Text] [Related]
6. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. Berezhnoy A; Castro I; Levay A; Malek TR; Gilboa E J Clin Invest; 2014 Jan; 124(1):188-97. PubMed ID: 24292708 [TBL] [Abstract][Full Text] [Related]
7. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy. Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318 [TBL] [Abstract][Full Text] [Related]
8. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8 Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114 [TBL] [Abstract][Full Text] [Related]
9. Tumor cells and memory T cells converge at glycolysis: therapeutic implications. Karthikeyan S; Geschwind JF; Ganapathy-Kanniappan S Cancer Biol Ther; 2014 May; 15(5):483-5. PubMed ID: 24556820 [TBL] [Abstract][Full Text] [Related]
11. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. Hu HM; Winter H; Urba WJ; Fox BA J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058 [TBL] [Abstract][Full Text] [Related]
12. The transcription factor Foxo1 controls central-memory CD8+ T cell responses to infection. Kim MV; Ouyang W; Liao W; Zhang MQ; Li MO Immunity; 2013 Aug; 39(2):286-97. PubMed ID: 23932570 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105 [TBL] [Abstract][Full Text] [Related]
14. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225 [TBL] [Abstract][Full Text] [Related]
15. Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection. Bellavance EC; Kohlhapp FJ; Zloza A; O'Sullivan JA; McCracken J; Jagoda MC; Lacek AT; Posner MC; Guevara-Patino JA J Immunol; 2011 Mar; 186(6):3309-16. PubMed ID: 21289306 [TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Gold JE; Zachary DT; Osband ME Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164 [TBL] [Abstract][Full Text] [Related]
17. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840 [TBL] [Abstract][Full Text] [Related]
18. FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma. Conde E; Casares N; Mancheño U; Elizalde E; Vercher E; Capozzi R; Santamaria E; Rodriguez-Madoz JR; Prosper F; Lasarte JJ; Lozano T; Hervas-Stubbs S Mol Ther; 2023 Jan; 31(1):48-65. PubMed ID: 36045586 [TBL] [Abstract][Full Text] [Related]
19. Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells. Shimizu K; Yamasaki S; Shinga J; Sato Y; Watanabe T; Ohara O; Kuzushima K; Yagita H; Komuro Y; Asakura M; Fujii S Cancer Res; 2016 Jul; 76(13):3756-66. PubMed ID: 27371739 [TBL] [Abstract][Full Text] [Related]
20. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]